Voxelotor is primarily used in the treatment of sickle cell disease, a genetic disorder that causes red blood cells to become misshapen and break down. It works by increasing the affinity of hemoglobin for oxygen, which helps to prevent the sickling of red blood cells. This reduces the likelihood of blockages in blood vessels, thereby decreasing the frequency of pain crises and other complications associated with the disease. Voxelotor is administered orally and is often prescribed for patients aged 12 years and older. It is considered a significant advancement in the management of sickle cell disease, offering a mechanism that directly targets the underlying pathology of the condition.